ǾÀÔ¿ñ±Õ¸º¾¯¾É

Æü¡¹°ì²ó¤Î¾Ð´é¡£¹¬¤»¤ËÀ¸¤­¤Æ¤¤¤ë¡£

Á´ÂÎɽ¼¨

[ ¥ê¥¹¥È ]



Ï¢ºÜ¡¡³¤³°ÏÀʸ¤ÈÏÂÌõ¡¡14/15

¡ú¡ú°ÎÂç¿¿¼ÂĶ¥¿¥Ö¡¼¸ø³«¡ú¡ú
¢£³¤³°ÏÀʸ¤ÈÏÂÌõ¡¡14/15
¢¡¥Õ¥é¥ó¥¹¡¢Êƹñ¡¢±Ñ¹ñ¡¢¶¦Æ±¸¦µæµ¡´Ø¡¦ÆüËܤâ»ñ¶â¢¡
¡ú¡úĶ¥¿¥Ö¡¼ÄãÊü¼ÍÀþÈïÇøÇ¯1·1mGyÇò·ìÉÂ531¿Í»àË´¥¬¥ó»àË´209¿ÍÅù²òÀÏ¡ú¡ú


¥Æ¡¼¥Ö¥ë 2¡¡»à¤Î¸¶°ø¤ÎÎßÀÑÀÖ¹ü¿ñÀþÎÌ Gy Åö¤¿¤ê ERR¢£³¤³°ÏÀʸ¤ÈÏÂÌõ¢¡¥Õ¥é¥ó¥¹¡¢Êƹñ¡¢±Ñ¹ñ¡¢¶¦Æ±¸¦µæµ¡´Ø¡¦ÆüËܤâ»ñ¶â¢¡ÆüËܷкѿ·Ê¹


¥Æ¡¼¥Ö¥ë 2 »à¤Î³Æ¼ï¸¶°øÅù¤ÎÎßÀѰìÍ÷ɽ ¹ñºÝ¤¬¤ó¸¦µæµ¡´Ø¡Ê¥Õ¥é¥ó¥¹¡Ë¤Ê¤É£³¥«¹ñ¤Î¸¦µæµ¡´Ø¤Î¶¨ÎÏKIKITATA2015.11.9.ÈÇ



¤³¤Î¸¦µæ¤Ï¡¢Ä¹°ú¤¤¤¿ÄãÍÑÎÌÊü¼ÍÀþÈïÇø¤ÈÇò·ìɤδ֤Υݥ¸¥Æ¥£¥Ö¤Ê´Ø·¸¤Î¶¯¤¤¾Úµò¤òÄ󶡤·¤Þ¤¹¡£

ÈïÇø¡ÊÉþÍѡˤϡ¢Èó¾ï¤ËÄ㤤Ψ¤ÇÆÀ¤é¤ì¤Þ¤·¤¿¡ÊÊ¿¶Ñ1ǯ¤Ë¤Ä¤­1·1mGy¡¢SD 2·6¡Ë¡£ Çò·ìÉ»à˴Ψ

²æ¡¹¤Ï¡¢¥Õ¥é¥ó¥¹¡¢Êƹñ¡¢±Ñ¹ñ¡¢308 297¿Í¤ÎÊü¼ÍÀþ¤ò¥â¥Ë¥¿¡¼¤µ¤ì¤¿Ï«Æ¯¼Ô¤Î°ìÃĤò½¸¤á¤Þ¤·¤¿¡£
°ìÃĤϡ¢¹ç·×·2200Ëü¿Í
²æ¡¹¤Ï¡¢Çò·ìÉ¡¢¥ê¥ó¥Ñ¼ð¤È¿ȯÀ­¹ü¿ñ¼ð¤Ëµ¯°ø¤¹¤ë»à¤ò³Î¤«¤á¤Þ¤·¤¿¡£

²æ¡¹ ¤Ï¡¢CLL ¤ò½ü¤¯Çò·ìɤˤè¤ë 531 ¤Î»àË´¼Ô¤òµ­Ï¿¤·¤¿ 814 ¤Ë¤è¤ë¥ê¥ó¥Ñ¼ð¤È¿ȯÀ­¹ü¿ñ¼ð 293¡£

»ñ¶âÄó¶¡¤ÏÆüËܤθüÀ¸Ï«Æ¯¾ÊÅù


¡ÖLancet·ÇºÜ¤ÎINWORKSÇò·ìÉÂÏÀʸ¡×
http://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(15)00094-0/abstract

ǯ1.1¥ß¥ê¥·¡¼¥Ù¥ë¥È¤ÇÎßÀÑ16¥ß¥ê¥·¡¼¥Ù¥ë¥È¤Ë¤Æ¡¢531¿Í¤¬Çò·ìɤǻàË´

ǯ1.1¥ß¥ê¥·¡¼¥Ù¥ë¥È¤ÇÎßÀÑ16¥ß¥ê¥·¡¼¥Ù¥ë¥È¤Ë¤Æ¡¢209¿Í¤¬¥¬¥ó¤Ç»àË´
 
ǯ1¥·¡¼¥Ù¥ë¥È¤ÇÇò·ìɤǻàË´¤Ï£´ÇܤËÁý²Ã

»²¹Í
¡ÚCT¸¡ºº¤Ç¤ÎÊü¼ÍÀþ¤Ë¤è¤ë¥¬¥óȯ¾É£²£´¡óÁý²Ã¡Û¡¡4.5¥ß¥ê¥·¡¼¥Ù¥ë¥È

»²¹Í
2015/11/5(ÌÚ) ¸á¸å 7:17¡¡¡¡http://blogs.yahoo.co.jp/kikitata3/34330140.html

2015/11/5(ÌÚ) ¸áÁ° 5:00¡¡¡¡http://blogs.yahoo.co.jp/kikitata3/34326093.html

2015/11/5(ÌÚ) ¸á¸å 8:14¡¡¡¡http://blogs.yahoo.co.jp/kikitata3/34330261.html

2015/11/3(²Ð) ¸á¸å 2:04¡¡¡¡http://blogs.yahoo.co.jp/kikitata3/34325450.html




estimated mortality in a cohort of 90 268 USA radiological technologists.
90 268¿Í¤ÎUSAÊü¼ÍÀþ³Ø²Ê³Øµ»½Ñ¼Ô¤Î°ìÃĤοäÄꤵ¤ì¤¿»à˴Ψ¡£
90 268 ÊÆ¹ñ¤ÎÊü¼ÍÀþµ»»Õ¤Î¥³¥Û¡¼¥È¤Î¿äÄê»à˴Ψ¡£
They reported that the leukaemia risk was doubled for technologists who had worked for more than 30 years compared with those who had worked for less than 10 years, but the cohort did not provide any information about doses received by the workers.
Èà¤é¤Ï¡¢10 ǯ̤ËþƯ¤¤¤Æ¤¤¤¿¿Í¤ÈÈæ³Ó¤µ¤ì¤¿ 30 ǯ°Ê¾åÁ°¤Ë¶Ð̳¤·¤Æ¤¤¤¿µ»»Õ¤Î¤¿¤á¤ÎÇò·ìÉ¥ꥹ¥¯¤Ï 2 Çܤ¬¡¢¥³¥Û¡¼¥È¤ÏϫƯ¼Ô¤¬¼õ¤±¤¿ÀþÎ̤ˤĤ¤¤Æ¤¹¤Ù¤Æ¤Î¾ðÊó¤òÄ󶡤·¤Ê¤«¤Ã¤¿¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£
10ǯ̤Ëþ¤Î´ÖƯ¤¤¤¿¿Í¡¹¤ÈÈæ³Ó¤·¤Æ30ǯ°Ê¾å¤Î´ÖƯ¤¤¤¿²Ê³Øµ»½Ñ¼Ô¤Î¤¿¤á¤Ë¡¢Çò·ìÉÂ´í¸±¤¬ÆóÇܤˤʤë¤È¡¢Èà¤é¤ÏÊó¹ð¤·¤Þ¤·¤¿¡¢¤·¤«¤·¡¢°ìÃĤÏϫƯ¼Ô¤Ë¤è¤Ã¤Æ¼õ¤±¼è¤é¤ì¤ëÉþÍѤ˴ؤ¹¤ë¾¯¤·¤Î¾ðÊó¤âÄ󶡤·¤Þ¤»¤ó¤Ç¤·¤¿¡£

In summary, this study provides strong evidence of an association between protracted low dose radiation exposure and leukaemia mortality.
Í×Ì󤹤ë¤È¡¢¤³¤Î¸¦µæ¤Ï¡¢Ä¹°ú¤¤¤¿ÄãÍÑÎÌÊü¼ÍÀþÈïÇø¤ÈÇò·ìÉ»à˴Ψ¤Î´Ö¤Î´Ø·¸¤Î¶¯¤¤¾Úµò¤òÄ󶡤·¤Þ¤¹¡£
Í×Ì󤹤ë¤È¡¢¤³¤Î¸¦µæ¤Ï¡¢Ä¹´üÄãÀþÎÌÊü¼ÍÀþ¤Î˽Ϫ¤ÈÇò·ìɤλà˴Ψ´Ö¤Î¥¢¥½¥·¥¨¡¼¥·¥ç¥ó¤Î¶¯ÎϤʾڵò¤òÄ󶡤·¤Þ¤¹¡£
At present, radiation protection systems are based on a model derived from acute exposures, and assumes that the risk of leukaemia per unit dose progressively diminishes at lower doses and dose rates.
37
¸½ºß¡¢Êü¼ÍÀþÊݸ¥¹¥Æ¥àµÞÀ­Ë½Ïª¤«¤éÇÉÀ¸¤·¤¿¥â¥Ç¥ë¤Ë´ð¤Å¤¤¤Æ¡¢Ã±°ÌÀþÎ̤¢¤¿¤ê¤ÎÇò·ìɤΥꥹ¥¯¤Ï¡¢ÄãÀþÎ̤ÈÀþÎÌΨ¤Ç½ù¡¹ ¤Ë¸º¾¯¤¹¤ëÁ°Äó¤È¤·¤Æ¤¤¤Þ¤¹¡£
¸½»þÅÀ¤Ç¤Ï¡¢¥·¥¹¥Æ¥à¤¬¤½¤¦¤Ç¤¢¤ëÊü¼ÍÀþËɸî¤Ï¡¢¿¼¹ï¤ÊϪ½Ð»þ´Ö¤ËͳÍ褹¤ë¥â¥Ç¥ë¤Ë´ð¤Å¤¤¤Æ¡¢Ã±°ÌÉþÍѤˤĤ­Çò·ìɤΥꥹ¥¯¤¬ÄãÍÑÎ̤ÈÀþÎÌΨ¤Ç¼¡Âè¤Ë¸º¾¯¤¹¤ë¤È²¾Äꤷ¤Þ¤¹¡£
37
Our results provide direct estimates of risk per unit of protracted dose in ranges typical of environmental, diagnostic medical, and occupational exposure.
²æ¡¹ ¤Î·ë²Ì¤Ï¡¢¥ê¥¹¥¯¿ÇÃÇ¡¢´Ä¶­¡¢°åÎÅ¡¢µÚ¤Ó¿¦¶È˽Ϫ¤Îŵ·¿Åª¤ÊÈϰϤÇŰú¤¯ÀþÎ̤Îñ°Ì¤´¤È¤ÎľÀÜ¿äÄê¤òÄ󶡤·¤Þ¤¹¡£
²æ¡¹¤Î·ë²Ì¤Ï¡¢´Ä¶­¡¢¿ÇÃÇ·ò¹¯¿ÇÃǤȿ¦¶ÈŪ¤ÊϪ½Ð¤ËÆÃÍ­¤ÎÈϰϤǡ¢Ä¹°ú¤¤¤¿ÉþÍѤÎñ°Ì¤Ë¤Ä¤­¡¢´í¸±¤ÎľÀܤοäÄê¤òÄ󶡤·¤Þ¤¹¡£

Contributors
¹×¸¥¼Ô
¹×¸¥¼Ô
DBR and AK had the idea for the study. DBR, AK, EC, RDD, MG, JAO'H, GBH, RH, KL, DL, MKS-B, and IT-C designed the study. KL and DL worked on provision of the French data,
DBR ¤È AK ¸¦µæ¤Î¤¿¤á¤Î¥¢¥¤¥Ç¥¢¤ò»ý¤Ã¤Æ¤¤¤¿¡£DBR¡¢AK¡¢EC¡¢RDD¡¢MG¡¢JAO'H¡¢GBH¡¢RH¡¢KL¡¢DL¡¢MKS-B¡¢¤½¤ì C À߷׸¦µæ¡£KL ¤È DL ¤Î¥Õ¥é¥ó¥¹¤Î¥Ç¡¼¥¿Ä󶡤˼è¤êÁȤߤޤ·¤¿
DBR¤ÈAK¤Ë¤Ï¡¢¸¦µæ¤Ë¤Ä¤¤¤Æ¤Î¥¢¥¤¥Ç¥¢¤¬¤¢¤ê¤Þ¤·¤¿¡£
DBR¡¢AK¡¢EC¡¢RDD¡¢MG¡¢JAO'H¡¢GBH¡¢RH¡¢KL¡¢DL¡¢£Í£Ë£ÓB¤ÈITC¤Ï¡¢¸¦µæ¤òÀ߷פ·¤Þ¤·¤¿¡£
KL¤ÈDL¤Ï¡¢¥Õ¥é¥ó¥¹¤Î¥Ç¡¼¥¿¤ÎÄ󶡤ǵ¡Ç½¤·¤Þ¤·¤¿¡¢

MKS-B and RDD worked on provision of the US data,
MKS B ¤È RDD ¤ÎÊÆ¹ñ¥Ç¡¼¥¿Ä󶡤˼è¤êÁȤߤޤ·¤¿
£Í£Ë£ÓB¤ÈRDD¤Ï¡¢Êƹñ¥Ç¡¼¥¿¤ÎÄ󶡤ǵ¡Ç½¤·¤Þ¤·¤¿¡¢
MG, JAO'H, and RH worked on provision of the UK data.
MG¡¢JAO'H¡¢¤ª¤è¤Ó RH ¤Ï¡¢¥¤¥®¥ê¥¹¤Î¥Ç¡¼¥¿¤ÎÄ󶡤˼è¤êÁȤߤޤ·¤¿¡£
MG¡¢JAO'H¤ÈRH¤Ï¡¢±Ñ¹ñ¥Ç¡¼¥¿¤ÎÄ󶡤˼è¤êÁȤߤޤ·¤¿¡£
MM managed, processed, and analysed the data.
MM ¤Ï¡¢´ÉÍý¡¢½èÍý¡¢¤ª¤è¤Ó¥Ç¡¼¥¿¤òʬÀϤ·¤Þ¤·¤¿¡£
MM¤Ï¡¢¥Ç¡¼¥¿¤ò´ÉÍý¤·¤Æ¡¢½èÍý¤·¤Æ¡¢Ê¬ÀϤ·¤Þ¤·¤¿¡£
IT-C analysed and assessed dosimetry data.
ITC¤Ï¡¢ÀþÎ̬Äê¥Ç¡¼¥¿¤òʬÀϤ·¤Æ¡¢É¾²Á¤·¤Þ¤·¤¿¡£
¤½¤ì C ʬÀϤ·¡¢ÀþÎ̬Äê¥Ç¡¼¥¿¤òɾ²Á¤·¤Þ¤·¤¿¡£
KL did the statistical analysis. KL and DBR wrote the initial draft of the report, which was revised and approved by all authors.
KL¤Ï¡¢Åý·×ʬÀϤò¤·¤Þ¤·¤¿¡£KL¤ÈDBR¤Ï¥ì¥Ý¡¼¥È¤ÎºÇ½é¤ÎÁð°Æ¤ò½ñ¤­¤Þ¤·¤¿¡£¤½¤·¤Æ¡¢¤½¤ì¤Ï½¤Àµ¤µ¤ì¤Æ¡¢¤¹¤Ù¤Æ¤ÎÃø¼Ô¤Ë¾µÇ§¤µ¤ì¤Þ¤·¤¿¡£
KL ¤Ï¡¢Åý·×ʬÀϤò¤·¤Þ¤·¤¿¡£KL ¤È DBR ¤Ï¡¢²þÄû¤µ¤ì¡¢¤¹¤Ù¤Æ¤ÎÃø¼Ô¤Ë¤è¤Ã¤Æ¾µÇ§¤µ¤ì¤¿¥ì¥Ý¡¼¥È¤ÎºÇ½é¤Î¥É¥é¥Õ¥È¤ò½ñ¤¤¤Æ¤¤¤Þ¤¹¡£
Declaration of interests
Íø³²´Ø·¸¼Ô¤ÎÀë¸À
Íø±×¤ÎÀë¸À
We declare no competing interests.
²æ¡¹¤Ï¡¢Íø³²´Ø·¸¤òÀë¸À¤·¤Þ¤»¤ó¡£
²æ¡¹ ¤Ï¶¥¹ç¤¹¤ëÍø±×¤òÀë¸À¤·¤Þ¤»¤ó¡£
Acknowledgments
¼Õ¼­¡¦¾µÇ§
¼õ¿®³Îǧ
This work was partly funded by the Centers for Disease Control and Prevention (5R03 0H010056-02) and the Ministry of Health,
¤³¤Î»Å»ö¤Ï¡¢¼ÀÉ´ÉÍýͽËÉ¥»¥ó¥¿¡¼¡Ê5R03 0H010056-02¡Ë¤ÈÊÝ·ò¾Ê¤Ë¤è¤Ã¤ÆÉôʬŪ¤Ë»ñ¶â¤ò¶¡µë¤µ¤ì¤Þ¤·¤¿¡¢
¤³¤ÎºîÉʤϡ¢°ìÉô¡¢¼ÀɤäͽËÉ (5R03 0 H 010056-02)¡¢ÊÝ·ò¾Ê¤ÎÃæ¿´¤Ë¤è¤Ã¤ÆÏŤï¤ì¤Æ¤¤¤¿
Labour and Welfare of Japan (GA No 2012-02-21-01) .
ÆüËÜ (GA ¤Ï 2012ǯ-02-21-01) ¤Î¸üÀ¸
ϫƯÅÞ¤ÈÆüËÜ¡ÊGA¤Ê¤·2012-02-21-01¡Ë¤ÎÊ¡»ã¡£
The construction of the French cohort was realised by the Institut de Radioprotection et de Sûreté Nucléaire, with partial funding from AREVA and Electricité de France.
¥Õ¥é¥ó¥¹¤Î¥³¥Û¡¼¥È¤Î·úÀߤÀ¤Ã¤¿ Institut de Êü¼ÍÀþËɸî¤Ë¤è¤Ã¤Æ¼Â¸½ et de Sûreté Nucléaire¡¢AREVA ¤ÈÅŵ¤¡¦ ¥É ¡¦ ¥Õ¥é¥ó¥¹¤«¤é»ñ¶â¤Î°ìÉô¤Ç¡£
ÉôʬŪ¤Ê»ñ¶âÄ󶡤¬AREVA¤ÈElectricité¥Ç¡¦¥Õ¥é¥ó¥¹¤«¤é¤Ë¤¢¤Ã¤Æ¡¢¥Õ¥é¥ó¥¹·³Àª¤Î·úÀߤϡ¢Institut¥ÇRadioprotection et¥ÇSû¥ì¡¼¥ÆNucléaire¤Ë¤è¤Ã¤ÆÍý²ò¤µ¤ì¤Þ¤·¤¿¡£
The Institut de Radioprotection et de Sûreté Nucléaire thanks all people from the French Atomic Energy Commission, AREVA, and Electricité de France who cooperated in the elaboration of the French cohort.
Institut de Êü¼ÍÀþËɸî et de Sûreté Nucléaire ¥Õ¥é¥ó¥¹¸¶»ÒÎϰѰ÷²ñ¡¢¥¢¥ì¥Ð¡¢Åŵ¤¡¦ ¥É ¡¦ ¥Õ¥é¥ó¥¹ ¥Õ¥é¥ó¥¹¤Î¥³¥Û¡¼¥È¤ÎÀºå̲½¤Ë¶¨ÎϤ·¤¿¤¹¤Ù¤Æ¤Î¿Í¡¹ ¤Î¤ª¤«¤²¤Ç¡£
¥Õ¥é¥ó¥¹¤Î¸¶»ÒÎϰѰ÷²ñ¡¢AREVA¤È¥Õ¥é¥ó¥¹·³Àª¤Î»Å¾å¤²¤Ë¤Ä¤¤¤Æ¶¨ÎϤ·¤¿Electricité¥Ç¡¦¥Õ¥é¥ó¥¹¤«¤é¡¢Institut¥ÇRadioprotection et¥ÇSû¥ì¡¼¥ÆNucléaire¤Ï¡¢¤¹¤Ù¤Æ¤Î¿Í¡¹¤Ë´¶¼Õ¤·¤Þ¤¹¡£
For the US contribution, funding was provided by the National Institute for Occupational Safety and Health, by the US Department of Energy through an agreement with the US Department of Health and Human Services, and through a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health (R03 OH-010056).
ÊÆ¹ñ¹×¸¥¤Î¤¿¤á¤Ë¡¢¹ñΩ¿¦¶ÈÊݰ¡¦·ò¹¯¶¨²ñ¤Ë¤è¤Ã¤Æ¡¢ÊƹñÊÝ·ò¼Ò²ñÊ¡»ã¾Ê¤È¤Î°ìÃפòÄ̤·¤Æ¤ÎÊÆ¹ñ¥¨¥Í¥ë¥®¡¼¾Ê¤Ë¤è¤Ã¤Æ¡¢¤½¤·¤Æ¡¢¹ñΩ¿¦¶ÈÊݰ¡¦·ò¹¯¶¨²ñ¡ÊR03 OH-010056¡Ë¤«¤é¥Î¡¼¥¹¥«¥í¥é¥¤¥ÊÂç³Ø¤Ë¤è¤Ã¤Æ¼õÎΤµ¤ì¤ëÊä½õ¶â¤òÄ̤·¤Æ¡¢»ñ¶âÄ󶡤ÏÄ󶡤µ¤ì¤Þ¤·¤¿¡£
ÊÆ¹ñ¤Î¹×¸¥¤Î»ñ¶â¤ÏϫƯ°ÂÁ´¤ÈÊÆ¹ñ¤Î¥¨¥Í¥ë¥®¡¼¾Ê¶¨Äê¤òÄ̤¸¤Æ¤Ç¡¢Êƹñ¤ÎÊÝ·òÊ¡»ã¾Ê¡¢·ò¹¯¤Î¤¿¤á¤Î¹ñΩ¸¦µæ½ê¤Ë¤è¤Ã¤ÆÄ󶡤µ¤ì¤ëÁ÷¼õ¿®¤Î½õÀ®¶â¤Ë¤è¤Ã¤Æ¹ñΩ¸¦µæ½ê¤«¤é¥Î¡¼¥¹¥«¥í¥é¥¤¥Ê¤ÎÂç³Ø¤Ë¤è¤Ã¤ÆÏ«Æ¯°ÂÁ´¤È·ò¹¯ (R03 ¥ª¥Ï¥¤¥ª-010056) ¤Î¤¿¤á¡£
The construction of the UK cohort was undertaken by Public Health England who operate the UK's National Registry for Radiation Workers.
Êü¼ÍÀþ¶È̳½¾»ö¼Ô¤Î¤¿¤á¤Î¥¤¥®¥ê¥¹¤Î¹ñÊÌÅÐÏ¿Êí¤ò±Ä¤à¸ø½°±ÒÀ¸¥¤¥ó¥°¥é¥ó¥É±Ñ¹ñ¥³¥Û¡¼¥È¤Î·úÀߤò°ú¤­¼õ¤±¤¿¡£
Êü¼ÍÀþϫƯ¼Ô¤Î¤¿¤á¤Ë±Ñ¹ñ¤Î¹ñ²ÈÅÐÏ¿½ê¤ò´ÉÍý¤¹¤ë¸ø½°±ÒÀ¸¥¤¥ó¥°¥é¥ó¥É¤Ë¤è¤Ã¤Æ¡¢±Ñ°ìÃĤηúÀߤϡ¢°ú¤­¼õ¤±¤é¤ì¤Þ¤·¤¿¡£




¡ÖÅìÆüËÜÂç¿ÌºÒ¸¶È¯¡×½ñ¸Ë¤Îµ­»ö°ìÍ÷

ÊĤ¸¤ë ¥³¥á¥ó¥È¡Ê3¡Ë

´é¥¢¥¤¥³¥ó

ÏÂÌõ¤Ïµ¡³£Åª¤Ê¤â¤Î¤Ç¤¹

ÏÂÌõ¤Ïµ¡³£Åª¤Ê¤â¤Î¤Ç¤¹¡£
ÆÉ¤ß¤Ë¤¯¤¯¡¢Íý²ò¡¦²ò¼á¤¬ÂçÊѤÀ¤È»×¤¤¤Þ¤¹¡£
¤·¤«¤·¡¢½ÐÍè¤ë¤À¤±ºî°ÙŪ¡¦×ó°ÕŪ¤Ç¤Ê¤¯É½¼¨¤µ¤ì¤ë¤È»×¤Ã¤Æ¤¤¤Þ¤¹¡£

¤ß¤ó¤Ê¤¬¡¢¤¤¤ÁÁ᤯¡¢½õ¤«¤ê¤Þ¤¹Íͤˡ¦¡¦¡¦¡¦¡¦¡¦

2015/11/8(Æü) ¸áÁ° 4:23 [ £Ë£É£Ë£É£Ô£Á£Ô£Á ]

´é¥¢¥¤¥³¥ó

¾åµ­¤ÎʸÀդϡ¢Áí¤Æ»ä¤ËÍ­¤ê¤Þ¤¹¡£

¤´¼«Í³¤Ë¡¢¤´»ÈÍѲ¼¤µ¤¤¡£

¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡£


žºÜ¤Ï¡¢¸æ¼«Í³¤Ç¤¹¡£ (°ìÉôžºÜ¤â¸æ¼«Í³¤Ç¤¹)

¤ß¤ó¤Ê¤¬¡¢¤¤¤ÁÁ᤯¡¢½õ¤«¤ê¤Þ¤¹Íͤˡ¦¡¦¡¦¡¦¡¦¡¦

2015/11/8(Æü) ¸áÁ° 4:24 [ £Ë£É£Ë£É£Ô£Á£Ô£Á ]

´é¥¢¥¤¥³¥ó

Ãí¡§µ­ºÜ¤Ë¸í¤ê¤¬¤¢¤ì¤Ð¡¢±óθ̵¤¯¤´¶µ¼¨²¼¤µ¤¤¡£

ÈãȽ¡¦·ãÎ塦ʸ¶ç¡¤¤Ê¤ó¤Ç¤â´¿·Þ

¤ß¤ó¤Ê¤¬¡¢¤¤¤ÁÁ᤯¡¢½õ¤«¤ê¤Þ¤¹Íͤˡ¦¡¦¡¦¡¦¡¦

2015/11/8(Æü) ¸áÁ° 4:24 [ £Ë£É£Ë£É£Ô£Á£Ô£Á ]


.
£Ë£É£Ë£É£Ô£Á£Ô£Á
£Ë£É£Ë£É£Ô£Á£Ô£Á
ÃËÀ­ / A·¿
¿Íµ¤ÅÙ
Yahoo!¥Ö¥í¥°¥Ø¥ë¥× - ¥Ö¥í¥°¿Íµ¤Å٤ˤĤ¤¤Æ
ͧ¤À¤Á(24)
  • bhz*****
  • 111
  • izu*****
  • ¹âº½¤Ç¥«¥Í¥ßÌý¾É¤ò¹Í¤¨¤ë
  • ¹ñ¶­¡¦´Ä¶­¡¦Îò»Ë³Ø½¬¥Ä¥¢¡¼
  • Îò»Ë¡õ´Ä¶­&¸øÆÁ¿´¥Ä¥¢¡¼
ͧ¤À¤Á°ìÍ÷

¥¹¥Þ¡¼¥È¥Õ¥©¥ó¤Ç¸«¤ë

¥â¥Ð¥¤¥ëÈÇYahoo!¥Ö¥í¥°¤Ë¥¢¥¯¥»¥¹¡ª

¥¹¥Þ¡¼¥È¥Õ¥©¥óÈÇYahoo!¥Ö¥í¥°¤Ë¥¢¥¯¥»¥¹¡ª

Æü ·î ²Ð ¿å ÌÚ ¶â ÅÚ
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

ɸ½à¥°¥ë¡¼¥×

Yahoo!¤«¤é¤Î¤ªÃΤ餻

¤è¤·¤â¤È¥Ö¥í¥°¥é¥ó¥­¥ó¥°

¤â¤Ã¤È¸«¤ë

[PR]¤ªÆÀ¾ðÊó

¤Õ¤ë¤µ¤ÈǼÀÇ¥µ¥¤¥È¡Ø¤µ¤È¤Õ¤ë¡Ù
¼Â¼Á2000±ß¤ÇÆÃ»ºÉʤ¬¤ª¼ê¸µ¤Ë
11¡¿30¤Þ¤Ç¥­¥ã¥ó¥Ú¡¼¥ó¼Â»ÜÃæ¡ª
ÏÃÂê¤Î¿·¾¦Éʤ¬º£¤À¤±¤â¤é¤¨¤ë¡ª
¥¸¥å¥ì¡¼¥à¥¢¥ß¥Î¡¡¥·¥å¡¼¥×¥ê¡¼¥à
¥×¥ì¥¼¥ó¥È¥­¥ã¥ó¥Ú¡¼¥ó

¤½¤Î¾¤Î¥­¥ã¥ó¥Ú¡¼¥ó


¤ß¤ó¤Ê¤Î¹¹¿·µ­»ö